Select Page

Press

  • EpiVax awarded $35K Montel Williams Foundation grant for multiple sclerosis research

    Posted on September 29, 2008 by epivax3
    https://www.beloblog.com/ProJo_Blogs/bizblog/2008/09/providencebased-1.html The Montel Williams MS Foundation today announced a grant to Providence-based Epivax, Inc., the first biotech-related company to be awarded a grant from the foundation. Epivax is a privately held company run by Anne Searls DeGroot that is dedicated to the development and implementation of computational immunology tools to benefit the biotechnology industry. The size of ...
    Read more
  • EpiVax Recieves $600,000 NIH Grant to Further Research in Type 1 Diabetes

    Posted on September 29, 2008 by epivax3
    EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH), to develop “Epi-13”, a novel therapeutic for the prevention and treatment of Type 1 diabetes, a ...
    Read more
  • EpiVax Presents Tolerance-inducing “Tregitopes” at Keystone Conference

    Posted on January 25, 2008 by epivax3
    EpiVax Presents Tolerance-inducing "Tregitopes" at Keystone Conference February 7, 2008 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, presented data at the Keystone Symposium on Tolerance and Transplantation (January 29-Feb 3, 2008), in Keystone Colorado confirming the activity of natural “Tregitopes” to induce tolerance to a wide range of antigens in vitro ...
    Read more
  • EpiVax Presents Tolerance-inducing “Tregitopes” at Keystone Conference

    Posted on January 25, 2008 by Annie De Groot
    EpiVax Presents Tolerance-inducing “Tregitopes” at Keystone Conference February 7, 2008 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, presented data at the Keystone Symposium on Tolerance and Transplantation (January 29-Feb 3, 2008), in Keystone Colorado confirming the activity of natural “Tregitopes” to induce tolerance to a wide range of antigens in vitro ...
    Read more
  • EpiVax Receives JDRF Industry Program Funding to Develop Diabetes Drug Using Natural “regulatory” T cells

    Posted on October 25, 2007 by epivax3
    October 25, 2007 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received funding from the Juvenile Diabetes Research Foundation (JDRF), the world’s largest charitable funder of Type 1 diabetes research, to develop “Epi-13,” a novel therapeutic for the prevention and treatment of type I diabetes, a ...
    Read more
  • EpiVax Receives JDRF Industry Program Funding to Develop Diabetes Drug Using Natural "regulatory" T cells

    Posted on October 25, 2007 by Annie De Groot
    October 25, 2007 (Providence, RI)—- EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received funding from the Juvenile Diabetes Research Foundation (JDRF), the world’s largest charitable funder of Type 1 diabetes research, to develop “Epi-13,” a novel therapeutic for the prevention and treatment of type I diabetes, a ...
    Read more
  • EpiVax awarded $590,000 SBIR for Immunoinformatics-driven TB Vaccine

    Posted on September 25, 2007 by epivax3
    The National Institutes of Health, National Institute Of Allergy And Infectious Diseases awarded a grant in the amount of $590,912 to EpiVax, Inc. in support of the development of a multi-epitope TB vaccine. This two-year award will allow EpiVax, to pursue pre-clinical studies leading to the optimization of its TB genome-derived DNA vaccine for the ...
    Read more
  • EpiVax Awarded a Grant for Hemophilia Therapy

    Posted on July 25, 2007 by epivax3
    PROVIDENCE BUSINESS NEWS By David Ortiz A Providence-based biotechnology pharmaceutical firm that genetically engineers new vaccines has received a $528,313 grant to begin developing a novel treatment for hemophilia. EpiVax Inc. will use the grant, from the National Institutes of Health, to reengineer Factor VIII, a clotting agent in the blood that is deficient in hemophiliacs. ...
    Read more
  • EpiVax funded to advance research on a new, improved “Botox”

    Posted on March 25, 2007 by epivax3
    February 26, 2007 (Providence, RI)—- EpiVax, Inc, a leader in genome-derived vaccines, announced today that it has received a grant to reengineer botulinum toxin, a protein that is used for cosmetic purposes (the most commonly used brand is known as “Botox”) and which is also used as a revolutionary therapeutic for movement disorders categorized as ...
    Read more
  • EpiVax wins SBIR Phase I grant totaling $993,771 to Develop Smallpox Vaccine

    Posted on June 15, 2005 by epivax3
    Providence, RI, December 17, 2004—EpiVax, Inc, a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities, and pharmaceutical companies, has been awarded a BioDefense Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the ...
    Read more
  • EpiVax Is Awarded H. Pylori SBIR Grant by National Institutes of Health

    Posted on June 1, 2005 by epivax3
    PROVIDENCE, RI — 04/27/2005 — EpiVax, Inc., a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities and pharmaceutical companies, today announced that it was awarded a $600,000 Phase I Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The grant award ...
    Read more
  • EpiVax moves to new facility at 146 Clifford Street including office and laboratory space

    Posted on November 25, 2004 by epivax3
    EpiVax moves to new facility at 146 Clifford Street including office and laboratory space
    Read more
  • EpiVax wins SBIR Phase I grant totaling $859,773 to Develop Tularemia Vaccine

    Posted on September 1, 2004 by epivax3
    Providence, RI, September 8, 2004—EpiVax, Inc, a leading provider of protein and genome analysis services, vaccine components, and vaccine candidates to researchers, government agencies, universities, and pharmaceutical companies, has been awarded a BioDefense Phase I Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National ...
    Read more
  • EpiVax signs Master Services Agreement with Amgen

    Posted on July 25, 2004 by epivax3
    EpiVax signs Master Services Agreement with Amgen
    Read more
  • EpiVax renews technology license with Brown University

    Posted on August 25, 2003 by epivax3
    EpiVax renews technology license with Brown University
    Read more

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here